share_log

bluebird bio | 8-K: Current report

bluebird bio | 8-K: Current report

bluebird bio | 8-K:重大事件
美股sec公告 ·  04/26 16:18
Moomoo AI 已提取核心信息
On April 24, 2024, bluebird bio, Inc. received a notice from The Nasdaq Stock Market LLC indicating the company is not in compliance with Nasdaq Listing Rule 5250(c)(1) due to a delay in filing its Annual Report on Form 10-K for the year ended December 31, 2023. The company has until June 24, 2024, to submit a plan to regain compliance and may be granted an extension until October 14, 2024, to file the report. The delay is attributed to the need to restate financial statements for the year ended December 31, 2022, and unaudited financial information for the first three quarters of 2023 and 2022. The restatements are related to the identification of embedded leases and the treatment of non-lease components in lease agreements, which are not expected to impact...Show More
On April 24, 2024, bluebird bio, Inc. received a notice from The Nasdaq Stock Market LLC indicating the company is not in compliance with Nasdaq Listing Rule 5250(c)(1) due to a delay in filing its Annual Report on Form 10-K for the year ended December 31, 2023. The company has until June 24, 2024, to submit a plan to regain compliance and may be granted an extension until October 14, 2024, to file the report. The delay is attributed to the need to restate financial statements for the year ended December 31, 2022, and unaudited financial information for the first three quarters of 2023 and 2022. The restatements are related to the identification of embedded leases and the treatment of non-lease components in lease agreements, which are not expected to impact the company's cash position or revenue. bluebird bio intends to submit a compliance plan before the deadline and file the 2023 Form 10-K as soon as possible. The company issued a press release on April 26, 2024, to announce the receipt of the Nasdaq notice. The notice does not immediately affect the listing of the company's securities on Nasdaq.
2024年4月24日,蓝鸟生物公司收到纳斯达克股票市场有限责任公司的通知,表明由于延迟提交截至2023年12月31日止年度的10-K表年度报告,该公司未遵守纳斯达克上市规则5250(c)(1)。该公司必须在2024年6月24日之前提交恢复合规的计划,并可能获准将提交报告的期限延长至2024年10月14日。延迟归因于需要重报截至2022年12月31日的年度的财务报表,以及2023年和2022年前三个季度的未经审计的财务信息。重报与嵌入式租赁的确定和租赁协议中非租赁部分的处理有关,预计不会影响公司的现金状况或收入。bluebird bio打算在截止日期之前提交合规计划,并尽快提交2023年10-K表格。该公司于2024年4月26日发布了一份新闻稿,宣布收到纳斯达克的通知。该通知并未立即影响该公司证券在纳斯达克的上市。
2024年4月24日,蓝鸟生物公司收到纳斯达克股票市场有限责任公司的通知,表明由于延迟提交截至2023年12月31日止年度的10-K表年度报告,该公司未遵守纳斯达克上市规则5250(c)(1)。该公司必须在2024年6月24日之前提交恢复合规的计划,并可能获准将提交报告的期限延长至2024年10月14日。延迟归因于需要重报截至2022年12月31日的年度的财务报表,以及2023年和2022年前三个季度的未经审计的财务信息。重报与嵌入式租赁的确定和租赁协议中非租赁部分的处理有关,预计不会影响公司的现金状况或收入。bluebird bio打算在截止日期之前提交合规计划,并尽快提交2023年10-K表格。该公司于2024年4月26日发布了一份新闻稿,宣布收到纳斯达克的通知。该通知并未立即影响该公司证券在纳斯达克的上市。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息